{
  "id": "b977ce2abce2c23a",
  "title": "F . Hoffmann - La Roche Ltd : Roche fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis ( PPMS ) ",
  "description": "20260207T213000Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-02/67643058-f-hoffmann-la-roche-ltd-roche-s-fenebrutinib-is-the-first-investigational-medicine-in-over-a-decade-that-reduces-disability-progression-in-primary-p-399.htm",
  "published_at": "20260207T213000Z",
  "fetched_at": "2026-02-08T00:36:26.400151+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-02/67643058-f-hoffmann-la-roche-ltd-roche-s-fenebrutinib-is-the-first-investigational-medicine-in-over-a-decade-that-reduces-disability-progression-in-primary-p-399.htm",
    "url_mobile": "",
    "title": "F . Hoffmann - La Roche Ltd : Roche fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis ( PPMS ) ",
    "seendate": "20260207T213000Z",
    "socialimage": "https://www.finanznachrichten.de/chart-roche-holding-ag-gs-aktie-intraklein-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}